TSE:MDP FY2026 EPS Estimate Boosted by Leede Financial

Medexus Pharmaceuticals Inc. (TSE:MDP) – Stock analysts at Leede Financial lifted their FY2026 earnings per share (EPS) estimates for shares of Medexus Pharmaceuticals in a research note issued to investors on Wednesday, January 22nd. Leede Financial analyst D. Loe now anticipates that the company will earn $0.29 per share for the year, up from their prior estimate of $0.22. Leede Financial currently has a “Strong-Buy” rating on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

MDP has been the subject of several other research reports. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 17th. Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective on the stock in a report on Wednesday, January 8th. Finally, Stifel Nicolaus upped their target price on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a buy rating and five have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Strong Buy” and a consensus price target of C$5.58.

Medexus Pharmaceuticals Stock Down 5.9 %

Shares of MDP opened at C$4.47 on Friday. The company has a market capitalization of C$109.65 million, a price-to-earnings ratio of 89.40 and a beta of 1.96. Medexus Pharmaceuticals has a 52-week low of C$1.47 and a 52-week high of C$5.56. The stock has a 50 day moving average price of C$3.14 and a 200 day moving average price of C$2.69.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.